Search results for "Herpes Zoster"

showing 10 items of 21 documents

Preventing and managing herpes zoster: key actions to foster healthy aging

2015

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can prot…

Gerontologymedicine.medical_specialtyPopulation ageingAgingSettore MED/17 - Malattie InfettiveImmunosenescenceCost-Benefit AnalysisHerpes zosterAlternative medicinePsychological interventionSocio-culturaleDiseaseSettore MED/42 - Igiene Generale E ApplicataQuality of life (healthcare)medicineHerpes Zoster VaccineHumansHerpes zoster; Immunosenescence; Vaccine; Aged; Cost-Benefit Analysis; Herpes Zoster; Herpes Zoster Vaccine; Humans; Italy; Middle Aged; Quality of Life; Aging; Vaccination; Aging; Geriatrics and GerontologyAgedbusiness.industryTetanusVaccinationHerpes zoster; Immunosenescence; Vaccine; Aging; Geriatrics and GerontologyMiddle Agedmedicine.diseaseComorbidityVaccinationItalyQuality of LifeGeriatrics and GerontologybusinessVaccineVaccine; Herpes zoster;Immunosenescence
researchProduct

Ospedalizzazioni per Zoster e neuropatia post-erpetica in Sicilia: quali sono le comorbosità più frequenti?

2016

INTRODUZIONE L’Herpes Zoster (HZ) e la Nevralgia Post-Erpetica (NPE) sono patologie frequenti nell’adulto, specialmente in chi è affetto da comorbosità, e possono essere causa di ospedalizzazione. Oltre il 95% degli adulti italiani, avendo contratto la varicella, ne sono a rischio e l’unica METODIca di prevenzione è la vaccinazione. MATERIALI É stato condotto uno studio retrospettivo osservazionale delle Schede di Dimissione Ospedaliera dei soggetti residenti in Sicilia dal 2007 al 2015 per analizzare le variabili socio- demografiche e sanitarie tra cui la presenza di comorbosità dei ricoverati per HZ e PHN. I codici ICD9-CM utilizzati per identificare i casi HZ e NPE sono stati 053-053.9 p…

Herpes zoster neuropatia post-erpetica comorbosità SiciliaSettore MED/42 - Igiene Generale E Applicata
researchProduct

[Herpes Zoster and its prevention in Italy. Scientific consensus statement].

2014

In this paper, an Italian group of experts presents a revision of the available data about epidemiology and prevention of Herpes Zoster (HZ). HZ is an acute viral diseases caused by the reactivation of Varicella Zoster Virus (VZV). HZ is characterized by neurological and dermatological symptoms with a dermatomeric localization. The reactivation of the virus from the latent status in the sensitive ganglia increases with age and failing cell mediated immunity. In Europe, more than 95% of adults presents antibodies against VZV. Incidence of HZ is similar all over the world, related to the age of the population: from 2-3/1000 persons/year in the age group 20 to 50 years to 5/1000 in the 60 year…

AdultAged 80 and overClinical Trials as TopicEvidence-Based MedicineSettore MED/17 - Malattie InfettiveIncidenceSocio-culturaleNeuralgia Postherpeticconsensus statementMiddle AgedSettore MED/42 - Igiene Generale E ApplicataHerpes ZosterAge DistributionItalyRisk Factors80 and overNeuralgiaHerpes Zoster VaccineHumansAdult; Age Distribution; Aged; Aged 80 and over; Clinical Trials as Topic; Evidence-Based Medicine; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Italy; Middle Aged; Neuralgia Postherpetic; Risk Factors; SicilyPostherpeticSicilyprevention of herpes zosterAgedIgiene e sanita pubblica
researchProduct

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review

2019

Background Vaccine adjuvants are compounds that significantly enhance/prolong the immune response to a co-administered antigen. The limitations of the use of aluminium salts that are unable to elicite cell responses against intracellular pathogens such as those causing malaria, tuberculosis, or AIDS, have driven the development of new alternative adjuvants such as QS-21, a triterpene saponin purified from Quillaja saponaria. Purpose The aim of this review is to attempt to clarify the mechanism of action of QS-21 through either receptors or signaling pathways in vitro and in vivo with special emphasis on the co-administration with other immunostimulants in new adjuvant formulations, called a…

InflammasomesT-Lymphocytesmedicine.medical_treatmentHerpes zosterPharmaceutical ScienceMonophosphoryl Lipid AAPCs antigen presenting cellsMiceCMI cell mediated immunity0302 clinical medicineDrug DiscoveryHerpes Zoster VaccineMedicineNSCLC non small cell lung carcinomaCancerImmunity CellularVaccines Synthetic0303 health sciencesImmunogenicityIl-2 interleukine 2HIV human immunodeficiency virusLipid A030220 oncology & carcinogenesisCytokinesMolecular MedicineDCs dendritic cellsNK natural killerAdjuvantTLR Toll-like receptorHerpes Zoster VaccineCD cluster of differentiationAntigen-Presenting CellsCTL cytotoxic T lymphocytesHZ herpes zosterMPL 3-deacylated monophosphoryl lipidVaccine adjuvantImmunoadjuvantArticleVZV varicella zoster virus03 medical and health sciencesImmune systemAdjuvants ImmunologicAntigenPAMPs pathogen-associated molecular patternsMalaria VaccinesPRRs pathogen recognition receptorsQS-21 Quillaja saponaria Molina-fraction 21AnimalsMHC major histocompatibility complexMtb Mycobacterium tuberculosis bacteriaSARS severe acute respiratory syndromeAntigen-presenting cellIFN-γ interferon-gamma030304 developmental biologyPharmacologybusiness.industryA-β amyloid-betaTNF-α tumor necrosis factor-alphaSaponinsQS-21MalariaQuillaja saponariaComplementary and alternative medicineTCR T-cell receptorLiposomesImmunologyKLH keyhole limpet hemocyaninbusinessdLN draining lymph nodesMAPK mitogen activated protein kinasePhytomedicine
researchProduct

[S1 Herpes zoster localization: acute urinary retention in woman].

2011

Acute urinary retention in women is rare. The varicella-zoster virus causes inflammatory lesions of the sensory-root ganglions, meninges and, less frequently, spinal cord. Herpes zoster has been reported to affect, although rarely, lower urinary tract innervations, and acute urinary retention can be thought to occur in the presence of sacral dermatome involvement. Usually it is located in S2–4 dermatome and the prognosis for acute urinary retention is benign resolving in about 20 days. We present a case in which the S1 dermatome was interested and acute urinary retention developed. After 10 days of specific therapy and self catheterism the problem resolved.

medicine.medical_specialtySacrumUrinary systemAcyclovirGastroenterologyAntiviral AgentsHerpes ZosterVirusS1 dermatomeInternal medicinemedicineHumansIntermittent Urethral CatheterizationUrinary retentionbusiness.industryMeningesGeneral MedicineMiddle AgedUrinary RetentionSpinal cordSacrumSurgerymedicine.anatomical_structureTreatment OutcomeDermatomeAcute DiseaseFemalemedicine.symptombusinessSpinal Nerve RootsUrologia
researchProduct

Postherpetic neuralgia and recalcitrant cystic lesions following herpes zoster: A case report and review of treatment options.

2020

Acute herpes zoster lesions in most cases are self-limited except in older and immunocompromised patients, wherein the pain can cause significant suffering. Postherpetic neuralgia is a painful situation for patients that can compromise the quality of life. Here, we report a 30-year-old healthy young man who developed treatment-resistant postherpetic neuralgia after herpes zoster (fourth/fifth thoracic segment) without any underlying immunocompromised state. He also developed some cystic lesions, which were removed by aspiration and surgery. The skin lesions improved 2 weeks after the surgery and postherpetic neuralgia was completely cured after 5 months, however cystic lesions recurred mult…

AdultMalemedicine.medical_specialtyNeuralgia PostherpeticDermatologyHerpes Zoster030207 dermatology & venereal diseases03 medical and health sciencesCystic lesion0302 clinical medicineRecurrencemedicineHumansTreatment resistantAgedPostherpetic neuralgiabusiness.industryTreatment optionsGeneral Medicinemedicine.diseaseDermatologynervous system diseasesbody regions030220 oncology & carcinogenesisQuality of LifeSkin lesionbusinessDermatologic therapyREFERENCES
researchProduct

Multidimensional Frailty and Vaccinations in Older People: A Cross-Sectional Study

2022

It is known that influenza, herpes zoster, pneumococcal and pertussis infections may increase morbidity and mortality in older people. Vaccinations against these pathogens are effective in older adults. Frailty seems to be an important determinant of vaccination rates, yet data supporting this association are still missing. Therefore, we aimed to investigate the prevalence of four recommended vaccinations (influenza, herpes zoster, pneumococcal and diphtheria-tetanus-pertussis) and the association with multidimensional frailty assessed using a self-reported comprehensive geriatric assessment tool, i.e., the multidimensional prognostic index (SELFY-MPI). Older participants visiting the outpa…

PharmacologySettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/09 - Medicina InternapneumococcuImmunologydiphtheria-tetanus-pertussisherpes zostermultidimensional prognostic index; vaccination; influenza; herpes zoster; pneumococcus; diphtheria-tetanus-pertussisvaccinationSettore MED/42 - Igiene Generale E Applicatamultidimensional prognostic indexdiphtheria-tetanus-pertussivaccination.Infectious DiseasesDrug DiscoveryPharmacology (medical)diphtheria-tetanus-pertussis; herpes zoster; influenza; multidimensional prognostic index; pneumococcus; vaccinationinfluenzapneumococcusVaccines; Volume 10; Issue 4; Pages: 555
researchProduct

Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review

2021

Abstract Introduction Although the COVID‐19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. Objective To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID‐19 vaccines. And to identify on whether COVID‐19 vaccine has temporal relationship between development of herpes zoster (HZ). Methods We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like “Shingles,” “Herpes zoster,” “Varicella zoster,” “COVID‐19,” “Vaccine,” “SARS‐CoV‐2.” No filters including country of publication, language…

MalePediatricsmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)herpes zosterReview ArticleDermatologyMalignancyCovidVaricella zosterChickenpoxCOVID‐19vaccinemedicineHerpes Zoster VaccineHumansAdverse effectSARS-CoV-2business.industryIncidence (epidemiology)Metabolic disorderCOVID-19Middle Agedmedicine.diseaseVaccinationFemalebusinessShinglesJournal of Cosmetic Dermatology
researchProduct

Localizzazione S1 di Herpes Zooster: un raro caso di ritenzione urinaria.

2011

Donna di 46 anni con ritenzione urinaria acuta e stipsi. Presentava piccola vescicola sul dorso del piede sinistro quale unica manifestazione di localizzazione di virus Herpes Zooster a livello sacrale S1. Viene riportato l'esame urodinamico e le risultanze dei test sierologici seriati specifici per l'infezione da virus Varicella Zooster. La paziente è guarita a seguito di terapia specifica con Acyclovir. Il caso riportato dimostra che anche il segmento sacrale S1 contribuisce al controllo della dinamica minzionale

Settore MED/07 - Microbiologia E Microbiologia ClinicaRitenzione d'urina Localizzazione S1 Herpes ZosterSettore MED/26 - NeurologiaSettore MED/24 - Urologia
researchProduct

Pharmacology and safety of tofacitinib in ulcerative colitis.

2020

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

Moderate to severePharmacologyHerpes ZosterArthritis Rheumatoid03 medical and health sciences0302 clinical medicineImmune systemPharmacokineticsPiperidinesNeoplasmsMedicineHerpes Zoster VaccineHumansJanus Kinase InhibitorsDrug InteractionsTofacitinibbusiness.industryImmunogenicityJanus Kinase 3Janus Kinase 1Venous Thromboembolismmedicine.diseaseUlcerative colitisBioavailabilityPyrimidines030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeJanus kinasebusinessGastroenterologia y hepatologia
researchProduct